These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12019792)

  • 1. BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance.
    Hansen SG; Cope TA; Hruby DE
    Biotechniques; 2002 May; 32(5):1178, 1180, 1182-7. PubMed ID: 12019792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.
    Franke CA; Rice CM; Strauss JH; Hruby DE
    Mol Cell Biol; 1985 Aug; 5(8):1918-24. PubMed ID: 3018537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.
    Mackett M; Smith GL; Moss B
    J Virol; 1984 Mar; 49(3):857-64. PubMed ID: 6321770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts.
    Pfleiderer M; Falkner FG; Dorner F
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():2957-62. PubMed ID: 8847500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.
    Smith KA; Stallard V; Roos JM; Hart C; Cormier N; Cohen LK; Roberts BE; Payne LG
    Vaccine; 1993; 11(1):43-53. PubMed ID: 8427036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker.
    Sánchez-Puig JM; Blasco R
    Biotechniques; 2005 Nov; 39(5):665-6, 668, 670 passim. PubMed ID: 16312215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant host range selection of vaccinia recombinants by rescue of an essential gene.
    Holzer GW; Gritschenberger W; Mayrhofer JA; Wieser V; Dorner F; Falkner FG
    Virology; 1998 Sep; 249(1):160-6. PubMed ID: 9740787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Green fluorescent protein expressed by a recombinant vaccinia virus permits early detection of infected cells by flow cytometry.
    Domínguez J; Lorenzo MM; Blasco R
    J Immunol Methods; 1998 Nov; 220(1-2):115-21. PubMed ID: 9839932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Set of vectors for the expression of histidine-tagged proteins in vaccinia virus recombinants.
    Galindo I; Lorenzo MM; Blasco R
    Biotechniques; 2001 Mar; 30(3):524-6, 528-9. PubMed ID: 11252789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient host range selection for genetic engineering of modified vaccinia virus Ankara.
    Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G
    Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a novel set of transfer vectors to study vaccinia virus replication and foreign gene expression.
    Dvoracek B; Shors T
    Plasmid; 2003 Jan; 49(1):9-17. PubMed ID: 12583996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins.
    Himly M; Pfleiderer M; Holzer G; Fischer U; Hannak E; Falkner FG; Dorner F
    Protein Expr Purif; 1998 Dec; 14(3):317-26. PubMed ID: 9882565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes.
    Lülf AT; Freudenstein A; Marr L; Sutter G; Volz A
    Virology; 2016 Dec; 499():322-330. PubMed ID: 27741426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus.
    Cochran MA; Mackett M; Moss B
    Proc Natl Acad Sci U S A; 1985 Jan; 82(1):19-23. PubMed ID: 3855541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCR-based method for the introduction of mutations in genes cloned and expressed in vaccinia virus.
    Lorenzo MM; Blasco R
    Biotechniques; 1998 Feb; 24(2):308-13. PubMed ID: 9494734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.
    Laudermilch E; Chandran K
    J Mol Biol; 2021 Apr; 433(9):166896. PubMed ID: 33639215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Puromycin resistance (pac) gene as a selectable marker in vaccinia virus.
    Sánchez-Puig JM; Blasco R
    Gene; 2000 Oct; 257(1):57-65. PubMed ID: 11054568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection.
    Wong YC; Lin LC; Melo-Silva CR; Smith SA; Tscharke DC
    J Virol Methods; 2011 Jan; 171(1):295-8. PubMed ID: 21073901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective humoral immune response of Balb/C mice to Brucella abortus proteins expressed by vaccinia virus recombinants.
    Toth TE; Cobb JA; Boyle SM; Roop RM; Schurig GG
    Vet Microbiol; 1995 Jul; 45(2-3):171-83. PubMed ID: 7571368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assay of recombinant vaccinia virus-encoded neomycin phosphotransferase in infected eukaryotic cell lysates.
    Franke CA; Hruby DE
    J Virol Methods; 1987 May; 16(1-2):147-54. PubMed ID: 3038938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.